No association between a reduced CYP2D6 activity and a poorer outcome was found in this cohort of tamoxifen treated early breast cancer patients in a current clinical setting, where adjuvant tamoxifen is mainly used upfront for patients at a lower risk of recurrence. The gene discussed is CYP2D6; the disease is breast cancer.